(Reuters) -Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro. Shares of the company rose ...
Eli Lilly said its sees growth from key treatments such as Trulicity, Taltz and Verzenio driving 2021 revenues to around $28 billion. Eli Lilly said 2020 revenues should come in between $24.2 ...
Firstly, let us look at Eli Lilly’s stock performance. LLY stock has seen extremely strong gains of 345% from levels of $170 ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
Eli Lilly shares were marked6.6% lower in early Thursday afternoon trading following the earnings release to change hands at $319.51 each, erasing all of the stock's six-month gains.
Eli Lilly reported its current treatment for ulcerative colitis, Omvoh, was effective in helping those with Crohn's disease.
The radiopharmaceutical revolution rolls on as Eli Lilly and Co. builds on its prowess in the space with a deal that could ...
Eli Lilly reported first-quarter adjusted profit that topped Wall Street's expectations. The company also hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Soaring sales of Eli Lilly’s hugely popular diabetes and weight loss drugs Mounjaro and Zepbound prompted ...
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.